Latest Rigel Pharmaceuticals Inc. Stories
SOUTH SAN FRANCISCO, Calif., May 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 8th Annual JMP Securities Research Conference in San Francisco on Wednesday, May 20th at 2:00 p.m. PT. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes...
SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2009. For the first quarter of 2009, Rigel reported a net loss of $29.9 million, or $0.82 per share, compared to a net loss of $27.3 million, or $0.79 per share, in the first quarter of 2008. Weighted average shares outstanding for the first quarters of 2009 and 2008 were 36.7 million and 34.4 million, respectively....
SOUTH SAN FRANCISCO, Calif., March 27 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at Citi's 4th Annual Biotech Day in New York City on Wednesday, April 1st at 10:40 a.m. EDT. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the...
Preclinical Rationale for Clinical Trial Presented at USCAP Meeting SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the enrollment of the first patient in a Phase 2, multi-center clinical trial of R788 (fostamatinib disodium) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). The clinical trial's primary objective is to assess the efficacy of R788, an orally bio-available Syk kinase...
SOUTH SAN FRANCISCO, Calif., March 12 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will be presenting at the Keystone Symposia conference on Extrinsic Control of Tumor Genesis and Progression taking place next week in Vancouver, British Columbia. Presentation Date: Tuesday, March 17, 2009 Session: Poster Session 2 Poster Number: 206 Poster Title: Suppression of Breast Cancer Metastasis by R428, a Novel Small Molecule...
SOUTH SAN FRANCISCO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2008. (Logo: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO) For the fourth quarter of 2008, Rigel reported a net loss of $33.4 million, or $0.91 per share, compared to a net loss of $19.0 million, or $0.61 per share, in the fourth quarter of 2007. Weighted average shares outstanding for the...
RADNOR, Pa., Feb. 20 /PRNewswire/ -- The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP: Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Northern District of California on behalf of purchasers of securities of Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) ("Rigel" or the "Company") between December 13, 2007 and October 27, 2008 inclusive (the "Class Period"). If you wish to...
SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will delay further partnership discussions regarding R788 until after results from the Phase 2b clinical trials of R788 are available. The company expects that these results, involving approximately 650 additional patients, will substantially further the understanding of R788's potential and may therefore drive enhanced economics in a possible deal. The...
SOUTH SAN FRANCISCO, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Company will host a conference call with simultaneous webcast on Tuesday, February 3, 2009 at 8:30 am EST (5:30 am PST). Members of Rigel's senior management team will provide an update on the Company's business plans and programs. Conference Call and Webcast Information To access the live call, please dial 800-299-7098 (domestic) or 617-801-9715...
SOUTH SAN FRANCISCO, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, Rigel's chairman and chief executive officer, will participate in a panel discussion at the 2008 RBC Capital Marketing Healthcare Conference. The panel, entitled, "New Drugs and Targets for Inflammation and Rheumatology", will take place on Wednesday, December 10, 2008 at 10:00 a.m. EST at The Westin Times Square Hotel in New York City. To...
